Authors
Dennis I Narcisse, Hwasoon Kim, Lisa M Wruck, Amanda L Stebbins, Daniel Muñoz, Sunil Kripalani, Mark B Effron, Kamal Gupta, R David Anderson, Sandeep K Jain, Saket Girotra, Jeff Whittle, Catherine P Benziger, Peter Farrehi, Li Zhou, Tamar S Polonsky, Faraz S Ahmad, Matthew T Roe, Russell L Rothman, Robert A Harrington, Adrian F Hernandez, W Schuyler Jones
Publication date
2024/1/1
Journal
Diabetes care
Volume
47
Issue
1
Pages
81-88
Publisher
American Diabetes Association
Description
OBJECTIVE
Patients with diabetes mellitus (DM) and concomitant atherosclerotic cardiovascular disease (ASCVD) must be on the most effective dose of aspirin to mitigate risk of future adverse cardiovascular events.
RESEARCH DESIGN AND METHODS
ADAPTABLE, an open-label, pragmatic study, randomized patients with stable, chronic ASCVD to 81 mg or 325 mg of daily aspirin. The effects of aspirin dosing was assessed on the primary effectiveness outcome, a composite of all-cause death, hospitalization for myocardial infarction, or hospitalization for stroke, and the primary safety outcome of hospitalization for major bleeding. In this prespecified analysis, we used Cox proportional hazards models to compare aspirin dosing in patients with and without DM for the primary effectiveness and safety outcome.
RESULTS
Of 15,076 patients, 5,676 (39%) had …
Total citations
20242
Scholar articles
DI Narcisse, H Kim, LM Wruck, AL Stebbins, D Muñoz… - Diabetes care, 2024